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Abstract 
AIM: To access the effectiveness, safety and tolerance of methotrexate (MTX) in psoriatic arthritis (PsA) 
treatment. 
METHODS:  We recruit 37 patients, admitted at HCMC Hospital of Dermato-Venereology from 1/2016 to 3/2017, 
with MTX dosage ranging from 10 mg to 15 mg per week.  
RESULTS: Skin lesion response after 12 weeks improved PASI 50: 40.5%, PASI 75: 24.3%. Disease activity 
score decreased after 12 weeks with ∆DAS28 = -1.43 + 0.79, 37.8% PsA achieved complete remission. Nausea 
and vomiting were 8.1%. These symptoms were mild and transient. We did not stop MTX usage. The rate of 
elevating SGPT 2-3 times as much as the upper limit of the normal range was 2.7%. 
CONCLUSION: We finally demonstrated that the rate of treatment response in Vietnam is the same as 
demonstrated by foreign authors in other countries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The incidence rate of psoriatic arthritis is 6-
42%. Among drugs treating psoriatic arthritis, 
methotrexate (MTX) is approved by the Food and 
Drug Administration (FDA) in psoriatic arthritis 
treatment. Although the efficacy of MTX is variable 
among researches, it is the drug recommended by 
European League against Rheumatism-EULAR for 
moderate and severe psoriatic arthritis treatment [1].  
Methods 
 
Because of the absence of research or 
summary report on MTX in the treatment of psoriatic 
arthritis in Vietnam, we recruited 37 psoriasis arthritis 
patients, Between January 2016 to March 2017, 
admitted to HCMC Hospital of Dermato-Venereology.  
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Results 
 
Female made up the majority (67.57%), more 
than male. 15.6% of patients had the family history of 
psoriasis as shown in Table 1.  
Table 1: Characteristic of samples 
Characteristic Distribution 
Sex: n (%) 
Male 
Female 
 
12(32.43) 
25(67.57) 
Age: mean (SD), year 48(13) 
Family history: n (%) 7(18.2) 
PA duration: median, year 1(1-8) 
Habit: 
Smoking: n (%) 
Drinking: n (%) 
 
3(8.11) 
7(18.9) 
Swollen joints: median 2(1-18) 
Painful joints: median 1(1-14) 
ESR. mm/h: median 50(14-158) 
Pain, 100 mm VAS: median 30(10-80) 
First sign: 
Skin psoriasis: n (%) 
Arthritis: n (%) 
Skin psoriasis and arthritis at the same time: n (%) 
 
26(70.27) 
10(27,03) 
1(2.7) 
Nail dystrophy: n (%) 31(83.78) 
Joint deformity: n (%) 15(37) 
Peripheral arthritis: n (%) 30(81.08) 
Sacroiliitis: n (%) 2(5.41) 
Spinal arthritis: n (%) 6(16.22) 
Distal interphalangeal joint arthritis: n (%) 13(35.14) 
HLA B27(+): n (%) 12(32.4) 
HLA Cw06(+): n (%) 1(2.7) 
HLA DR7(+): n (%) 12(32.4) 
 
Most cases (70.27%) had skin psoriasis 
before arthritis. Joint deformity rate was high (37.0%). 
Peripheral arthritis rate was also significant (81.08%), 
and the next was distal interphalangeal joint arthritis 
(31.3%). Nail dystrophy was also familiar (83.78%). 
Positive HLA-B27 and HLA-DR7 percentage was 
32.5% and 32.4% respectively while the positivity for 
HLA Cw06 in our research was 2.7%. 
Every patient stopped therapy with NSAIDs 
(non-steroidal anti-inflammatory drugs) and with 
DMARD (disease-modifying antirheumatic drug) at 
least 2 weeks and 1 month before, respectively. 
After 12 weeks treatment by MTX, at dosage 
10-15mg PO q12hr for 3 sequential doses per week. 5 
mg Folic acid was used 24 hours after taking MTX; 
skin lesions were improved. 40.5%, 24.3% and 37.8% 
achieved PASI 50, PASI 75 and PASI 90, respectively 
as shown in Table 2, in comparison with Laura’s study 
in which 27.2% patients reached PASI 75 [2]. 
Table 2: Efficacy of MTX in the treatment of psoriasis 
 
Treatment monitoring indexes  
Before 
treatment 
After 4 weeks After 8 weeks After 12 
weeks 
n % n % n % n % 
PASI  
PASI 50 
PASI 75 
PASI 90 
   
4 
1 
0 
 
10.8 
2.7 
0.0 
 
10 
5 
4 
 
27.0 
13.5 
10.8 
 
15 
9 
6 
 
40.5 
24.3 
16.2 
DAS 28 
> 5.1 
From 3.2 to 5.1 
From 2.6 to <  
5.1 
< 2.6 
 
11 
20 
6
* 
0 
 
29.7 
54.1 
16.2 
0 
 
6 
20 
4 
7 
 
16.2 
54.1 
10.8 
18.9 
 
0 
21 
6 
10 
 
 
56.8 
16.2 
27.0 
 
0 
16 
7 
14 
 
 
43.2 
18.9 
37.8 
DAS28 -1,4 + 0,8 
 (*)
 Psoriatic arthritis with bad prognosis: > 5 joints are affected, damage on X-ray, severe 
inflammatory reaction, injury beside joints, especially dactylitis.  
 
At week 8, 27% psoriatic arthritis patients 
achieved remission (Table 2), no severe arthritis 
patients left. After 12 weeks, 37.8% of patients 
reached alleviation, which is compatible with the study 
of Laura et al. in which 22.4% patients accomplished 
complete remission.  
The side effects at week 12 were mostly 
nausea and vomiting (8.1%). Fatigue and alopecia 
had the same rate (2.7%). These side effects were 
transient, and there was no need for treatment. Other 
side effects noted were elevated SGPT (2.7%), 
hemoglobin decreased (2.7%), neutropenia (2.7%) 
(Table 3). 
Table 3: The abnormality on subclinical tests 
Side effects n % 
Fatigue 1 2.7 
Nausea/Vomiting 2 5.4 
Alopecia 1 2.7 
Fever/Chill 0 0 
Pneumocitis 0 0 
SGPT elevation 
1.5 – 2 ULR
*
 (60 – 80 U/L) 
>2 – 3 ULR
*
 (81 – 120 U/L) 
 
2 
1 
 
5.4 
2.7 
Hemoglobin decrement above 2 g/dL 1 2.7 
White blood cells below the normal range 
(< 5.0 x10
9
/L) 
1 2.7 
Neutrophils below the normal range 
(< 1,8 x 10
9
/L) 
1 2.7 
Platelets below the normal range 
(< 140 x 10
3
/L) 
0 0 
(*)
 ULR: The upper limit of the normal range. 
 
 
 
Discussion 
 
Female was twice as likely as a man to get 
psoriatic arthritis, which was higher than the result of 
Reich’s study suggesting the proportion of males was 
58% [3]. This difference may be the characteristic of 
psoriatic arthritis in Vietnam because psoriasis relates 
to genetic and races.  
Joint deformity rate was also significant (37%) 
which was higher than the rate suggested in Moll and 
Wright research, 5% [4]. Nail dystrophy rate was 
83.78% which was compatible with those of Scarpa, 
63% [4] So patient with psoriasis vulgaris having nail 
change should be monitored to discover arthritis. The 
psoriatic arthritis duration was about 0.8 (0.1-2.9) year 
on median which is lower than the study of Gabrielle 
et al., (1-5) year on median) [5]. So most of our 
patients had suffered from prolonged arthritis before 
we did our research. 
Based upon our and published experiences, 
MTX is effective and affordable in psoriatic arthritis, 
affecting both skin lesions and joint damage. The 
price is more affordable than many biologic agents [6], 
[7], [8], [9], [10], [11], [12].  
We finally demonstrated that the rate of 
treatment response in Vietnam is the same as 
demonstrated by foreign authors in other countries. 
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